Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Axogen (Nasdaq: AXGN) announced it will release its second quarter 2026 financial results on Wednesday, July 29, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. Phone access is via (877) 407-0993 or (201) 689-8795, with webcast and replay on the Axogen Investors webpage.
Details
News Market Reaction – AXGN
On Jul 15, the day this news came out, AXGN closed 0.13% below the previous close. Our momentum scanner recorded 2 alerts in the available session data.
Data tracked by StockTitan Argus for the Jul 15 session.
Key Figures
- Q2 2026 release date
- July 29, 2026
- Scheduled financial results announcement date
- Conference call time
- 8:00 a.m. ET
- Start time for Q2 2026 investor call
- Toll-free dial-in
- (877) 407-0993
- Investor call phone access
- Direct dial-in
- (201) 689-8795
- Investor call phone access
Previous Earnings date Reports
-
Scheduled Q1 2026 results date and investor call details.
-
Announced Q4 and full-year 2025 results release timing and call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company's website at www.axogeninc.com.
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.